The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Classic psychedelics produce altered states of consciousness that individuals often interpret as meaningful experiences. Across a number of human studies, when the participant-rated intensity of the overall drug effects are statistically controlled for, certain subjective effects predict therapeutic and other desirable outcomes. Underlying neurobiological mechanisms are likely necessary but not sufficient to confer full and enduring beneficial effects. We propose that the subjective effects of psychedelics are necessary for their enduring beneficial effects and that these subjective effects account for the majority of their benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because psychedelics are not only beneficial in populations suffering from psychopathologies, but also for those without, enhancing social and cognitive skills such as empathy and creativity, but also general well-being (18, 112).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These associations could reflect target engagement (ketamine-induced glutamate release), leading to dissociative effects, a subsequent elicitation of synaptogenesis and resultant antidepressant response 28,56,57 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, in this state, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decentration, potentially leading to therapeutic outcomes [42, 43].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Given the dose-response relationship between the glutamate surge, synaptogenesis and antidepressant response following ketamine administration 28,56,57 , it is possible that the relationship between derealization and increased SV2A density observed here is mediated by glutamate release.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Self-citationNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citation
Cited by
Items 401–500 of 541
Optimizing psychedelic compounds for neuropsychiatric therapy
Thompson, S. M. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01004-7 · Cited by 2
“These powerful alterations of consciousness are described as intensely spiritual and emotionally meaningful and are thus thought by many to be essential to the antidepressant response [3].”
BackgroundThe Promise of Psychedelic Research
Peritore, C. (2022) · Future Drug Discovery · doi:10.4155/fdd-2021-0012 · Cited by 3
Pharmakotherapie, Psychotherapie oder „Superplacebos“? Wirkmechanismen der Therapie mit Psychedelika
Gründer, G., Brand, M., Färber, L. V., Kärtner, L., Kunz, L. C., Rohrmoser, B., Scharf, D., Schmitz, C. N., Spangemacher, M., & Mertens, L. J. (2024) · Die Psychotherapie · doi:10.1007/s00278-024-00709-6 · Cited by 2
Psychedelic Experiences and the Enactive Approach
Meling, D., & Scheidegger, M. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780192844064.013.9 · Cited by 3
McCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2021) · doi:10.31234/osf.io/xqzu2 · Cited by 2
Language Models Learn Sentiment and Substance from 11,000 Psychoactive ExperiencesPreprint
Friedman, S. F., & Ballentine, G. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.02.494544 · Cited by 1
“This is especially true for therapeutic psychedelic experiences, where the subjective emotional content of a trip correlates with clinical efficacy (1).”
BackgroundFacilitating real-life creative insight through psychedelic virtual realityPreprint
Siimon, T., Tulver, K., Kaup, K., Vasser, M., & Aru, J. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/zth7f · Cited by 5
Chwyl, C., Elvenes, O. S., Kleven, A. S. R., Kongshaug, E. W., Luoma, J. B., Pilecki, B. C., & Næss, E. T. (2025) · Research Square · doi:10.21203/rs.3.rs-6874539/v1 · Cited by 2
Strika-Bruneau, L., Fauvel, B., Dupuis, D., & Benyamina, A. (2023) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2023.01.003 · Cited by 1
Psychedelics: Recent Philosophical Discussions
Letheby, C. (2024) · Springer eBooks · doi:10.1007/978-94-017-8706-2_101-1 · Cited by 2
Slunecko, T. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00417 · Cited by 2
Wirkmechanismen antidepressiver Pharmakotherapie: Gehirn und Psyche – Körper und Umwelt
Spangemacher, M., Reinwald, J., Adolphi, H., Kärtner, L., Mertens, L. J., Schmitz, C. N., & Gründer, G. (2025) · Der Nervenarzt · doi:10.1007/s00115-024-01786-3 · Cited by 1
Soto-Angona, Ó., Rodríguez‐Urrutia, A., Ramos‐Quiroga, J. A., Álvarez-Bobo, Ó., Oña, G., Rosal, S. P., París-Pérez, J., & Wolff, M. (2025) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2025.100923 · Cited by 1
Lee, S. J., Epland, C., Kaitz, N., Shiyanbola, O. O., & Wenthur, C. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-12613-3 · Cited by 1
“…modifiers are often deployed uniformly across all study participants at a given site, a growing body of research has begun to identify how psychological constructs, personality traits, and social and contextual factors modulate therapeutic outcomes for psychedelic studies 8,10,12–14 , 21– 25 .”
Herrmann, F. M., Jones, G. M., Low, D. M., Zech, J. M., Carhart-Harris, R. L., & Kettner, H. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.09.007 · Cited by 1
Villiger, D. (2025) · Philosophy Compass · doi:10.1111/phc3.70059 · Cited by 1
“Preliminary evidence indicates that the more “mystical” patients rate their psychedelic experience, the greater the therapeutic effects tend to be (Ko et al. 2022; Yaden and Griffiths 2021).”
Yan, K., Ni, C., Kuo, Y.-Y., & Chen, M. (2025) · European Journal for Philosophy of Science · doi:10.1007/s13194-025-00679-9 · Cited by 1
“This includes debates about the necessity of subjective experience for therapeutic efficacy (Olson 2020; Yaden & Griffiths 2020), ethical concerns about patient vulnerability and autonomy during altered states (Villiger & Trachsel 2023; Barber & Dike 2023; Jacobs 2023), and calls for specialized…”
Matthews, S. C., Greco, A., Rastelli, C., & Nia, A. B. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1448043 · Cited by 3
“They contend that providing patients with similar conditions with different experiences and a range of therapeutic outcomes is an advantage, evidence of the multifaceted functionality of psychedelics and their potential role in personalized treatment regimens (35).”
InfluentialPerkins, D., Halman, A., Urokohara, A., Palumbo, J., Low, M., Ruffell, S., Coelho, N. L. G., Collins, L., Norman, A. F., & Sarris, J. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-25767-x · Cited by 1
Abreu, C. C., Biorac, A., Baldessarini, R. J., & Vázquez, G. H. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251392429 · Cited by 3
“14,15 These neuroplastic changes promoted synaptogenesis, particularly in the prefrontal cortex and hippocampus—regions implicated in mood regulation and cognitive processing.”
Mehmood, M., Bremler, R., Spriggs, M. J., Kettner, H., Roseman, L., Damgaard, L., Carhart-Harris, R. L., Erritzøe, D., & Zeifman, R. J. (2025) · Psychedelic Medicine · doi:10.1177/28314425251392251 · Cited by 4
“26 For instance, higher levels of mystical (i.e., a sense of unity and spirituality), 12,16,27 – 29 and emotional breakthrough (i.e., overcoming dif fi cult feelings and experiencing cathar-sis) 18 experiences are generally associated with treatment outcomes in psychedelic trials 28 (for an…”
From Science to Pleasure: Justifications of the Use of Classic Psychedelics in Finland
Tsupari, M., & Hupli, A. (2025) · Nordic Studies on Alcohol and Drugs · doi:10.1177/14550725251408251 · Cited by 3
Riedel, M., McAlpine, R. G., Sparby, T., & Sacchet, M. D. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100039 · Cited by 2
Lewis, S. P. (2026) · Palliative & Supportive Care · doi:10.1017/s1478951526101801 · Cited by 1
“Some have argued that these subjective effects are necessary for enduring benefit (Yaden and Griffiths 2021).”
Raj, G., & Bhargav, H. (2026) · Journal of Applied Consciousness Studies · doi:10.4103/jacs.jacs_24_25 · Cited by 1
Psychological support in psychedelic-assisted therapy clinical trials: A systematic review
Brusky, B., M’Baïlara, K., Alla, F., & Barrault, M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261424204 · Cited by 2
Pottie, E., Vertriest, E., Martínez-Afani, D., Soares, B. A., Cassels, B. K., & Stove, C. P. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00352 · Cited by 1
Negrine, J. J., Bright, S. J., Barratt, M. J., Pennell, M., Barnett, A., Bennett–Levy, J., & Piatkowski, T. M. (2026) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2026.2645025 · Cited by 1
Deutsch, A., Contreras, L. E., Kratina, S., & Mayo, L. M. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261433836 · Cited by 1
“Some believe that the subjective effects of psychedelics are an important and even necessary factor in facilitating positive outcomes, 8 although this remains a topic of debate in the field.”
5-HT 1A receptor blockade potentiates the subjective effects of DMT
Zahid, Z., Strassman, R. J., Qualls, C., & Nayak, S. M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261443696 · Cited by 1
“Evidence suggest that the psychological changes elicited by the acute subjective experience may play an integral role in the long-term therapeutic and well-being outcomes (Yaden and Griffiths, 2021).”
Belinger, L., Rieser, N. M., Engeli, E., Becciolini, L., Clamote, M., Pribiš, M., Saissi, F., Florineth, G. A., Hehl, N. L., Herdener, M., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112879 · Cited by 1
Psychedelics produce enduring enhancement of reward responsiveness in male rats
Thomas, C. W., LaMalfa, K. S., Whelan, T. P., Blackmore, T., Golden, C. T., Pizzagalli, D. A., Bergman, J., Gilmour, G., & Kangas, B. D. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02475-2 · Cited by 1
Gattuso, J. J., Kamal, A., Payet, J. M., Havaux, K., Hendey, J., Bezcioglu, B., Phelan, Z. J., Orchard, M., Bhanot, D., Hale, M. W., et al. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02501-3 · Cited by 1
Strika-Bruneau, L., Elhssaini, C., Fauvel, B., Kervadec, E., Bezo, A., Amirouche, A., Benyamina, A., & Roméo, B. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261473436 · Cited by 2
“However, pharmacological effects alone are unlikely to fully account for the sustained therapeutic benefits in PAP (Estric et al., 2025; Gründer et al., 2024; Yaden and Griffiths, 2020).”
The DEA report on ayahuasca risks: “Science” in service of prohibition?
Labate, B. C., Ermakova, A. O., Sloshower, J., Coelho, N. L. G., Palhano-Fontes, F., Antunes, H. F., de Assis, G. L., Cavnar, C., de Araújo, D. B., & Ribeiro, S. T. G. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00279 · Cited by 1
Ibogaína: un psicodélico atípico con potencial antiadictivo
(2023) · Revista de Psiquiatría del uruguay · doi:10.46706/psi/87.1.2 · Cited by 1
Psilocybin, moralization and psychotherapy: a scoping review and a case report
Loria, E., Lalumera, E., & D’Imperio, A. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2389962 · Cited by 1
“More generally, researchers tend to agree that subjective experiences and not just the drug are the healing factor (Noorani & Martell, 2021; Letheby & Gerrans, 2017; Yaden & Griffiths, 2020).”
Introduction: philosophy and psychedelic psychiatry
Letheby, C., & Gerrans, P. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0001 · Cited by 1
Canello, T., Tlaie, A., Chalise, K., Schölvinck, M. L., Pia, L., & Havenith, M. N. (2026) · Scientific Reports · doi:10.1038/s41598-026-59995-6 · Cited by 3
Do undergraduates’ views of psychedelics relate to the context for psychedelic use?
Petrovitch, D., Allen, J. V., Mitchell, S. M., & Littlefield, A. K. (2025) · Drug Science Policy and Law · doi:10.1177/20503245241308747 · Cited by 2
Neuroaesthetics of the psychedelic state
Hooper, J., Stoliker, D., Wolfe, K., & Hutchison, K. E. (2025) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2025.109238 · Cited by 3
Eckernäs, E., Koomen, J. V., Timmermann, C., Carhart-Harris, R. L., Röshammar, D., & Ashton, M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13037 · Cited by 1
“6 Consequently, accurate characterization of the relationship between drug exposure and the subjective psychedelic experience may prove important to guide dose decisions in future clinical studies.”
BackgroundA Needs Assessment of Older Hispanics in Omaha, Nebraska
DiMartino, D. R. (1979) · DigitalCommons@UNO · Cited by 1
Interpreting the rapidly changing landscape of spirit tech
Stockly, K. J., & Wildman, W. J. (2022) · Religion Brain & Behavior · doi:10.1080/2153599x.2022.2091010 · Cited by 1
Journey To The Centre Of The Mind: Psychedelic Treatment of Mental Health in Aotearoa
Lutyens, D. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.21904854 · Cited by 3
Ibogaine as a Treatment For Alcohol Use Disorder: a Preclinical Investigation
Falkenhaug, S. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.24225145 · Cited by 1
Therapeutic dissociation: From non-ordinary states to psychological transformationPreprint
Clingo, J. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/ypr7w · Cited by 1
Purple, R. J., Gupta, R., Thomas, C. W., Golden, C. T., Froudist‐Walsh, S., & Jones, M. W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.10.627734 · Cited by 1
Orlowski, P., Ruban, A., Szczypiński, J., Hobot, J., Bielecki, M., & Bola, M. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/k4xfg
The promises and pitfalls of facilitated spiritual experiences for the study of religion
Morgan, J. (2022) · Religion Brain & Behavior · doi:10.1080/2153599x.2022.2091008 · Cited by 1
“The suggestive findings that the subjective qualities of RSEs play a crucial role in their therapeutic effects (Yaden & Griffiths, 2021) indicates that some of the salubrious effects of religious and spiritual engagement may be mediated by the types of experiences cultivated by these practices.”
BackgroundPSILOCIBINO TERAPIJOS VEIKSMINGUMAS, GYDANT SUNKIĄ DEPRESIJĄ
Stumbraitė, A. (2022) · Health Sciences · doi:10.35988/sm-hs.2022.189
Yaden, D. B., & Newberg, A. B. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780190665678.003.0018
Self-citationOrigins: Triggers of Spiritual Experience
Yaden, D. B., & Newberg, A. B. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780190665678.003.0006
Self-citationFernandes-Nascimento, M. H., Negrão, A. B., Viana-Ferreira, K., Chaves, B. R., & Wang, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-2031631/v1
Language Models Learn Sentiment and Substance from 11,000 Psychoactive ExperiencesPreprint
Friedman, S. F., & Ballentine, G. (2022) · Research Square · doi:10.21203/rs.3.rs-1942143/v2
Dooper, M. (2022) · doi:10.55788/9af70cfc
Yaden, D. B., & van Elk, M. (2023) · Religion Brain & Behavior · doi:10.1080/2153599x.2022.2143407
Self-citationUtilizing new technologies to measure therapy effectiveness for mental and physical health
Ossie, J. E. (2023) · Digital USD (University of San Diego) · doi:10.22371/05.2023.006 · Cited by 2
Montgomery, C., Amaya, I. A., & Schmidt, T. T. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/s6dnr · Cited by 1
Hasler, F. (2023) · transcript Verlag eBooks · doi:10.14361/9783839445716 · Cited by 3
Unlocking the potential of psychedelics as medicine: Past obstacles and future outlooks
Kim, S. Y., Collins, R.-N., Teng, J., & Kalinowski, L. (2023) · MIT Science Policy Review · doi:10.38105/spr.osqbpecncp · Cited by 2
Membrane Permeation of Psychedelic CompoundsPreprint
Palmisano, V. F., Agnorelli, C., Fagiolini, A. M., Erritzøe, D., Nutt, D., Faraji, S., & Nogueira, J. J. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wlxmw
Toledo, M. M. V. (2023) · Cultura y Droga · doi:10.17151/culdr.2023.28.35.5
“Por ello, ha llegado a plantearse que los estados alterados de consciencia, así como las experiencias místicas que los individuos reportan tras el consumo del alcaloide, son necesarios para inducir un efecto antidepresivo sostenido (Yaden & Griffiths, 2021).”
BackgroundTraitements psychédéliques et soins en addictologie
Dauré, C., & Mallet, L. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77934-3.00069-x
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905 · Cited by 1
Kudrina, T., & Anna, K. (2023) · PSYCHOLOGICAL JOURNAL · doi:10.31108/1.2023.9.7.5
Idrees, S., Batool, A., Ahsan, S., & Rehman, J. (2024) · Pakistan Journal of Humanities and Social Sciences · doi:10.52131/pjhss.2024.v12i1.2068
“Even in the medical sphere of the drugs, many researches still accredit the therapeutic effects to the psychedelic induced states of consciousness (Yaden & Griffiths, 2020).”
BackgroundSchaller, A., Bourquin, G., Araujo, I. A., & Ljuslin, M. (2023) · Revue internationale de soins palliatifs · doi:10.3917/inka.242.0098
Ferreira, A. S. M., Martindale, S., & Luke, D. P. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00368
Assisted Psychedelic Psychotherapy: Rethinking the Paradigms of Psychiatric Care?
Mea, E., & Clemente, P. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1008154
Argyri, E. K., Fraser, F., Schilling, S., Robinson, O. C., Frick, A., Roseman, L., & Morgan, C. J. A. (2025) · Research Square · doi:10.21203/rs.3.rs-6178373/v1
Ayahuasca Retreats: The Role of Awe and Mystical Experiences in Well-Being
Maclean, B. R., Wilson, A. E., Allen, A., Schaffer, V., & Kannis‐Dymand, L. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2491378 · Cited by 1
Szpak, V., Maddams, S., Kim, A., Sager, Z. S., & Suzuki, J. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2025.0003
ANALYSIS OF THE PROBLEM OF CONSCIOUSNESS USING THE LAW OF THE ABSENCE OF ABSOLUTE NOTHINGNESS
Koç, V. (2025) · Akademik Hassasiyetler · doi:10.58884/akademik-hassasiyetler.1521791
Gunten, M. V., Russell, T., Stirland, I., Parks, S., Jenkins, T. G., & Edwards, J. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.12.658958 · Cited by 1
Goldway, N., Hendler, T., Jalon, I., Pasternak, Y., Sar-El, R., Mirelman, D., Sarna, N., Green, N., Agbaria, Y., & Sharon, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.25.666594
“This question reflects a broader debate about whether the subjective experiences elicited by psychoactive drugs are necessary for therapeutic outcomes 6,7 .”
Psychedelic agents for treatment-resistant depression
Gukasyan, N., & Griffiths, R. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00014-1
Self-citationPsychedelics’ Intoxicating Impact and Behavioural Dynamics
Wasti, A. Z. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1011743
Neurophysiological Markers of (Dis)Connectedness: Insights from Ketamine
Alnagger, N., Cardone, P., Montupil, J., Annen, J., Martial, C., Bonhomme, V. L., & Gosseries, O. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_8
Psychedelics: Recent Philosophical Discussions
Letheby, C. (2025) · Springer eBooks · doi:10.1007/978-94-024-2252-8_101
Neurocomputational evidence of sustained Self-Other mergence after psychedelicsPreprint
Mallaroni, P., Mason, N. L., Preller, K. H., Razi, A., Ereira, S., & Ramaekers, J. G. (2025) · medRxiv · doi:10.1101/2025.10.07.25337510
“It is thought that the (sub)acute subjective effects of psychedelics, such as ego dissolution and perceived connectedness, are predictive of therapeutic efficacy 39,40 .”
Dörfler, H. (2025) · Psychotherapie-Wissenschaft · doi:10.30820/1664-9583-2025-2-7
Epistemic phenomenology in psychedelic experience
Kochevar, C. (2025) · Synthese · doi:10.1007/s11229-025-05340-9
“The “mysticality” of psychedelic experiences, as measured by the Mystical Experience Questionnaire (MEQ), has taken center stage in many models (Yaden & Griffiths, 2021 ; Leonard & Brooks, 2025 ), but efforts to expand beyond the MEQ are underway (Yaden et al., 2024 ; Seragnoli et al., 2025).”
Hepburn, H., Ellenbroek, B. A., & Youn, J. (2025) · Psychedelics · doi:10.1016/j.psyche.2025.100005
Quantitative phosphoproteomics uncovers the signalling dynamics of hallucinogenic psychedelicsPreprint
Martin-Guerrero, S. M., Taddei-Tardon, M., Maltman, J. L., Potukanuma, S., González‐Maeso, J., Cutillas, P. R., & Lopez-Gimenez, J. F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.24.690190
Greguš, D., Hlinka, J., Tylš, F., Viktorin, V., Viktorinová, M., Bravermanová, A., Androvičová, R., Andrashko, V., Korčák, J., Nikolič, M., et al. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06983-9
Toscano, M. O., Civardi, S. C., & Durbano, F. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1014070
Laird, K. T., Siddarth, P., Ramos, A., Rich, R., Youssef, B., Schwartz, G. M., Sergi, K., Linton, M., Schwartzberg, L., Kelly, D. F., et al. (2026) · Psychedelic Medicine · doi:10.1177/28314425251413425 · Cited by 2
Wittenkeller, L. M., Gudelsky, G. G., Winhusen, T. M., & Amato, D. (2026) · Research Square · doi:10.21203/rs.3.rs-8544354/v1
Animal models in psychedelic research – Tripping over translationPreprint
Hay, M. Y. A. E., Cukić, A., Schölvinck, M. L., & Havenith, M. N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.14.699469
“Human studies have revealed that the subjective quality of acute psychedelic states predicts long-term therapeutic outcomes (52–54).”
Chwyl, C., Spata, A., Lucas, W., & Luoma, J. B. (2026) · BMC Psychology · doi:10.1186/s40359-025-03921-4
“These experiences have been proposed to contribute to persisting positive effects [14, 15], such as through increasing psychological and cognitive flexibility [16], openness to experiences, wellbeing, spirituality, and decreasing mental health symptoms [14, 17].”
Argyri, E. K., Fraser, F., Schilling, S., Frick, A., Robinson, O. C., Roseman, L., & Morgan, C. J. A. (2026) · npj Mental Health Research · doi:10.1038/s44184-026-00186-6 · Cited by 1
Lewis, B. R., Reid, M. C., Novick, A. M., Byrne, K., Niciu, M. J., Fonzo, G. A., Meyer, T. D., Feifel, D., El‐Mallakh, R. S., Soares, J., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251413490 · Cited by 3
“…experiential effects of classical psychedelics have been shown to correlate with therapeutic outcomes, there remain many questions as to the nature of this relationship and its consistency and therapeutic relevance (Goodwin et al., 2025; Ko et al., 2022; Olson, 2021; Yaden and Griffiths, 2021).”
Magnani, L., Ghirotto, L., Fesce, F., Re, T. S., Tanzi, S., Amerio, A., & Costanza, A. (2026) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2025-005689
“…crucial mediating role that acute subjective effects and contextual factors seem to have in defining the long-term effects caused by psychedelics, 65 66 as well as the need to manage any drug-induced challenging experience (eg, through assisted grounding practices 31 53 ), greatly justifies the…”
Baseline Mood and “Relational Triad” Predict Acute Qualities of Psychedelic Experience
Lipson, J., Kettner, H., Carhart-Harris, R. L., & Miller, L. (2026) · Behavioral Sciences · doi:10.3390/bs16020310
Transient or transformative? Psychedelics, agency and informed consent
Caporuscio, C. (2026) · Journal of Medical Ethics · doi:10.1136/jme-2025-111248 · Cited by 1
Henningfield, J. E., Barrett, F. S., Evans, S. M., Garcia‐Romeu, A., Garrett, B. E., Hienz, R. D., Lukas, S. E., Nayak, S. M., Strain, E. C., Weerts, E. M., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251398801 · Cited by 1
“Griffiths and Yaden wrote a pair of articles in JAMA Psychiatry discussing their concerns: “Keeping the Renaissance From Going Off the Rails” (also co-authored by Yaden’s wife, Mary (Bit) Yaden, a psychiatrist at Johns Hopkins) and “Preparing for the Bursting of the Psychedelic Hype Bubble” (also-co-authored by the ch…”
InfluentialSelf-citationSchlomberg, J. T., Meling, D., Grylka, R., Vasella, E. A., Augustinovic, D., & Scheidegger, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-39261-5
“…research, we argue that psychedelics should not be regarded as standalone pharmacological agents, but rather as context-sensitive catalysts whose therapeutic potential emerges through complex interactions between drug, the immediate and extended environment and an individual’s mindset 3,94,95 .”
Capacity Building Through Psychedelic-Assisted Therapy
Neitzke‐Spruill, L., & Rose, J. R. (2026) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2026.02.002 · Cited by 3
Metadata
- Authors
- Yaden, D. B., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-10
- Volume
- 4
- Issue
- 2
- Pages
- 568-572
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033615
- OpenAlex
- W3113263685
- Cited by
- 541
- References
- 28
- Citations by year
- 2026: 81 · 2025: 125 · 2024: 105 · 2023: 98 · 2022: 92 · 2021: 36 · 2020: 2
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Steven and Alexandra Cohen Foundation
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- psychedelics, subjective effects, treatment outcomes, altered states of consciousness, meaningful experiences, subjective experience, neurobiological mechanisms, psychedelic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.